Navigation Links
Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
Date:5/18/2009

Data on frequency of resistance development and safety presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SAN DIEGO, May 18 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced new data today from multiple studies of torezolid (TR-701), a novel antibiotic that is a potent inhibitor of gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Data presented at ECCMID demonstrate that MRSA and MSSA strains exposed in vitro to torezolid developed spontaneous resistance at a 16-fold lower frequency than strains exposed to linezolid (Zyvox(R)), the only drug of the oxazolidinone class currently marketed. Poster presentations on TR-701 also highlighted data characterizing torezolid's pharmacodynamics, high intracellular concentrations and resulting bactericidal activity. Human Phase 1 clinical studies showed that oral torezolid, administered at doses from 200 to 400 mg once a day over 21 days, is safe and well tolerated, and that its oral bioavailability is not affected by the administration of food.

"These new study results presented by Trius and external investigators validate the compound's increased potency and ability to reach bacterial pathogens in high concentration inside the tissues while also supporting a favorable safety and tolerability profile," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "As a result, there is significant interest from the medical community in torezolid, a second generation oxazolidinone, especially for the treatment of infections caused by S. aureus, including MRSA."

Posters/abstracts are available on the Trius Web site at www.triusrx.com/posters.

"As bacterial pathogens like MRSA continue developing resistance to current treatments, clinicians are more acutely aware of the need for an alternative that is less susceptible to resistance development along with a once a day dosing regimen which promotes higher compliance," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We will release top-line Phase 2 data in the coming weeks and plan to initiate Phase 3 testing in early 2010. Our goal is to provide physicians and patients with a best-in-class therapy as soon as possible."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Atrius Health Selects rL Solutions for Improved Patient Safety and Quality of Care
2. Trius Raises $30 Million in Series B Financing
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
5. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
6. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
7. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
8. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
9. American Association for Homecare Applauds Senate Subcommittee Efforts to Prevent Waste and Fraud in Medicare; Association Presents 13-Point Legislative Plan to Stop Waste and Fraud
10. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Linda, Ca (PRWEB) , ... December 07, 2016 , ... ... attain that funding is with useful, properly analyzed data. The team at Beckman Coulter ... to address the 'need for speed' and the need to operate in a GLP ...
(Date:12/7/2016)... ... December 07, 2016 , ... They are musicians and librarians, ... wives, brothers and fathers, from New England and around the nation. What do they ... are brought together in a beautiful and compelling new photographic exhibit debuting Friday, December ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
(Date:12/7/2016)... ... 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering ... is launching a charity drive to raise funds that will benefit the Marine Corps ... marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  Urinary catheters are used for ... other urological disorders. Urinary catheters include indwelling (Foley) ... Indwelling or Foley catheter is a flexible tube ... catheter is inserted into the bladder through the ... balloon attachment at one end of the catheter ...
(Date:12/7/2016)... YORK , Dec. 7, 2016 Global ... This report on the global hospital linen supply and ... of this market on a global and regional level. ... forecast for the period between 2015 and 2024 based ... the dynamics of the market along with their impact ...
(Date:12/7/2016)... , Dec. 7, 2016 A new investigational drug ... human clinical trials in search of the world,s first treatment ... publication of research findings today in the journal ... will be a watershed moment for millions of people living ... director of Van Andel Research Institute,s Center ...
Breaking Medicine Technology: